FOXO TECHNOLOGIES INC.

FOXO Technologies Inc. (NYSE American: FOXO) is an insurtech company focused on applying epigenetic biomarker science to life insurance underwriting and longevity-related products. The company went public in 2022 through a business combination with Delwinds Insurance Acquisition Corp., a SPAC that targeted the insurance sector. As of the January 2025 DEF 14A proxy filing, FOXO Technologies remains a publicly traded post-combination company navigating the operational and capital challenges common to early-stage insurtech issuers in the post-SPAC environment. The proxy reflects ongoing corporate governance activity at the company level. For the full FOXO filing history, deal terms, and real-time SPAC data, sign up for SpacDesk at spacdesk.com.